Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
New two-year data from the Phase 3 CAHtalyst Pediatric study showed durable reductions in androgen levels and glucocorticoid doses for patients taking CRENESSITY. Clinical improvements included 60% of overweight or obese patients achieving meaningful BMI improvement and 61% of those with insulin resistance no longer meeting criteria for the condition.
Key figures
- Drug Name
- CRENESSITY (crinecerfont)
- Phase Of Trial
- Phase 3
- Baseline acth pg ml
- 329
- Baseline 17 ohp ng dl
- 8682
- Baseline gc dose mg m2 day
- 16.4
- Month 24 acth change pg ml
- -157
- Month 24 17 ohp change ng dl
- -1924
- Study participants two year data
- 86
- Month 24 gc dose change mg m2 day
- -3.2
- Patients with improved bmi percent
- 60
- Patients no longer insulin resistant percent
- 61
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.